Our data revealed that GSTM3 did not significantly affect gemcitabine sensitivity of pancreatic cancer in vitro and in vivo, which implied that the oncogenic role of GSTM3TV2 in pancreatic cancer did not involve crosstalk with GSTM3 (Additional file 11: Figure S4). This evidence concerns the gene GSTM3 and pancreatic neoplasm.